GET DAILY SIGNALSAlphatec Holdings (ATEC) Falls -32% Over 30 Days After Q3 Earnings and Guidance Cut
Key Takeaways
- Alphatec Holdings (ATEC) shares have declined roughly 32% over the last 30 days, with most of the loss concentrated in a single session following its third-quarter earnings report.
- The stock fell about 38% on October 30, 2026, after Q3 revenue of $221.2 million missed estimates and management cut full-year revenue guidance.
- Full-year 2026 revenue guidance was lowered to approximately $862 million from roughly $882 million, citing lower biologics attachment rates, softer thoracolumbar volumes, EOS installation timing, and a temporary international supply constraint.
- Underlying operations stayed resilient, with case volumes up about 20%, new surgeon growth near 25%, and adjusted EBITDA margin expanding to roughly 17.3%.
- Several sell-side analysts trimmed price targets while maintaining Buy ratings, and multiple law firms announced shareholder investigations following the guidance cut.
- For deeper data, review ATEC's Price Targets, Earnings, and Forecast pages.
- Discover automated trading strategies on the Trending AI Robots page.
Alphatec Holdings (ATEC) Company Overview and Market Position
Alphatec Holdings, Inc. is a medical device company focused on the surgical treatment of spine disorders. Through its subsidiaries Alphatec Spine, EOS imaging, and SafeOp Surgical, the company develops implants, fixation systems, access systems, biologics, patient positioning technology, and intraoperative navigation. Its InformatiX platform integrates the EOS imaging system, the EOS Insight surgical planning software, the SafeOp Neural InformatiX monitoring system, and the Valence navigation-enabled robotics platform.
Alphatec differentiates itself by selling complete procedural solutions rather than individual products, with a particular strength in lateral spine surgery. Investors follow the stock closely because of its rapid revenue growth, expanding surgeon adoption, and progress toward sustained profitability in a spine market that includes competitors such as Globus Medical and Medtronic. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Alphatec Holdings (ATEC) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ATEC shares have fallen roughly 32%, declining from a close near $10.44 in mid-October to around $7.12 in recent trading. The move was abrupt rather than gradual: the stock traded near $11.37 on October 29, then plunged about 38% in a single session the following day — its worst one-day decline in more than a decade.
The quarterly picture tells a similar story. About three months earlier, the stock closed near $9.79, meaning ATEC has shed approximately 27% over the last quarter. Notably, the shares actually rallied through much of the period — climbing from the low $8.80s in early September to an intraday high above $12 in late October — before the post-earnings selloff erased those gains and pushed the stock to multi-month lows.
What Drove ATEC Stock Price in the Last 30 Days
The primary catalyst was the company's third-quarter 2026 earnings report, released after the market close on October 29. Total revenue grew 13% year over year to $221.2 million, but fell short of the roughly $225 million analysts had expected, and adjusted earnings per share of $0.09 came in below consensus. The shortfall was driven largely by lower biologics attachment — the bone-graft products sold alongside implants — as well as softer thoracolumbar procedure volumes.
Management also reduced full-year 2026 revenue guidance to approximately $862 million, down from the roughly $882 million it had reaffirmed in August, and trimmed free cash flow expectations. The guidance cut marked the second reduction of the year and raised questions about the company's ability to convert strong procedure growth into revenue per case. The market's reaction was amplified by the fact that the miss landed on biologics, the most variable part of Alphatec's growth model, and by broader sector weakness. In the following days, several analysts lowered price targets, and multiple law firms announced shareholder investigations into the company's prior statements.
What Drove ATEC Stock Performance Over the Last Quarter
Across the last three months, the dominant narrative has been a shift from steady accumulation toward a sharp repricing of growth expectations. Through September and most of October, the stock climbed as investors weighed Alphatec's strong procedural momentum — double-digit case-volume growth, record new surgeon additions, and improving margins — against concerns about execution in biologics and EOS capital placements.
The October earnings release crystallized those concerns. While adjusted EBITDA rose 46% to $38.3 million and gross margin improved nearly 200 basis points to about 72%, the revenue miss and guidance cut signaled that procedure growth was not translating into revenue-per-case expansion as expected. The combination of a second guidance reduction in six months, a thinner cash balance of about $80 million, and management's cautious tone on biologics recovery reset investor sentiment and compressed the stock's valuation multiple, leaving the shares sharply lower for the quarter despite the earlier rally.
ATEC Stock Forecast Drivers: What Investors Should Watch Next
The next major checkpoint is the company's fourth-quarter and full-year report, which will reveal whether biologics attachment recovered and whether the guidance reset proved conservative. Investors should monitor revenue per case, biologics contribution, thoracolumbar procedure trends, and EOS installation activity, alongside progress on the Valence robotics rollout and EOS Insight adoption. Competitive commentary from spine peers, macroeconomic pressure on elective procedure volumes, and any developments from the announced shareholder investigations may also influence sentiment. Management has indicated it is still finalizing its 2027 plan, so any forward commentary on growth and profitability targets will be closely watched. From what I see, this is important because the next update could clarify whether the recent pullback was overdone.
Trending AI Robots
In my own research process, I often review Tickeron’s marketplace of AI-driven trading bots to see how automated strategies are performing across different market conditions. The Trending AI Robots page highlights the top-performing and most relevant bots at any given time, covering a range of approaches from short-term momentum to longer-horizon trend-following. This gives me a practical way to compare methodologies and identify tools that align with my objectives when supplementing fundamental analysis with data-driven automation. For those looking to explore similar options, the Trending AI Robots page offers a useful starting point.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
ATEC in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 30, 2026
ATEC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 35 cases where ATEC's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ATEC's RSI Oscillator exited the oversold zone, 30 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +13.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATEC advanced for three days, in 266 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 204 of 253 cases where ATEC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATEC as a result. In 76 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for ATEC turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 34 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
ATEC moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ATEC crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. ATEC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ATEC's P/B Ratio (-95.212) is very low in comparison to the industry average of (4.142). P/E Ratio (-10.479) is within average values for comparable stocks, (3.291). ATEC's Projected Growth (PEG Ratio) (91.200) is very high in comparison to the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.980) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company with interests in medical equipment and supplies
Industry MedicalNursingServices